EHS
EHS

Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults




KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)—- $MRK #MRK–Merck and Ridgeback Statement on Positive FDA Vote for Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults

Source link

EHS
Back to top button